PEP-Therapy SAS:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:PEP-Therapy SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10999
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥33,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥67,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥101,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PEP-Therapy SAS (PEP-Therapy) is a medical biotechnology company that develops targeted therapies for the treatment of cancer. The company develops cell penetrating and interfering peptides for the intracellular delivery of targeted therapies. Its pipeline products include PEP-010. PEP-Therapy’s PEP-010 includes penetrating shuttle to deliver the active peptide into the cell, and an interfering active peptide blocking Caspase-9/PP2A interaction. The company’s product is used for the treatment of triple-negative breast cancer, lung and ovary cancers, and chronic lymphocytic leukemia. It also conducts clinical trials and licenses the novel therapeutic products and companion biomarkers to both pharmaceutical and biotech companies for their development and commercialization. PEP-Therapy is headquartered in Paris, France.

PEP-Therapy SAS – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
PEP-Therapy SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PEP-Therapy SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PEP-Therapy SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PEP-Therapy SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
PEP-Therapy SAS, Medical Devices Deals, 2012 to YTD 2018 9
PEP-Therapy SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
PEP-Therapy SAS, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
PEP-Therapy Raises USD1.4 Million in Seed Financing 11
Partnerships 12
Conectus Alsace Enters into Co-Development Agreement with PEP-Therapy 12
PEP-Therapy Enters into Co-Development Agreement with CleveXel Pharma 13
Licensing Agreements 14
PEP-Therapy Enters into Agreement with Inserm Transfert, Institut Curie and Pierre and Marie 14
PEP-Therapy SAS – Key Competitors 15
PEP-Therapy SAS – Key Employees 16
PEP-Therapy SAS – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
PEP-Therapy SAS, Pharmaceuticals & Healthcare, Key Facts 2
PEP-Therapy SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PEP-Therapy SAS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
PEP-Therapy SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PEP-Therapy SAS, Deals By Therapy Area, 2012 to YTD 2018 8
PEP-Therapy SAS, Medical Devices Deals, 2012 to YTD 2018 9
PEP-Therapy SAS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
PEP-Therapy Raises USD1.4 Million in Seed Financing 11
Conectus Alsace Enters into Co-Development Agreement with PEP-Therapy 12
PEP-Therapy Enters into Co-Development Agreement with CleveXel Pharma 13
PEP-Therapy Enters into Agreement with Inserm Transfert, Institut Curie and Pierre and Marie 14
PEP-Therapy SAS, Key Competitors 15
PEP-Therapy SAS, Key Employees 16
PEP-Therapy SAS, Other Locations 17

List of Figures
PEP-Therapy SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
PEP-Therapy SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
PEP-Therapy SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
PEP-Therapy SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
PEP-Therapy SAS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
PEP-Therapy SAS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
PEP-Therapy SAS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
PEP-Therapy SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
PEP-Therapy SAS, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[PEP-Therapy SAS:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Basin Electric Power Cooperative:企業の戦略・SWOT・財務分析
    Basin Electric Power Cooperative - Strategy, SWOT and Corporate Finance Report Summary Basin Electric Power Cooperative - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Microsoft Corp (MSFT):医療機器:M&Aディール及び事業提携情報
    Summary Microsoft Corporation (Microsoft) is a technology-based company that develops, licenses, and supports software products, services, and devices. The company offers a comprehensive range of operating systems, cross-device productivity applications, server applications, business solution applic …
  • Sui Northern Gas Pipelines Ltd (SNGP):企業の財務・戦略的SWOT分析
    Sui Northern Gas Pipelines Ltd (SNGP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • ifa systems AG (IS8):企業の財務・戦略的SWOT分析
    ifa systems AG (IS8) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Protokinetix Inc (PKTX):製薬・医療:M&Aディール及び事業提携情報
    Summary ProtoKinetix Inc (ProtoKinetix) is a biotechnology company that develops solutions for cell survival and health. The company develops anti-aging glycopeptides used to protect cell lines including hela cells, neonatal fibroblasts, adult fibroblast, human neuronal stem cells, CD34+ cells and k …
  • SPAR International:企業の戦略・SWOT・財務分析
    SPAR International - Strategy, SWOT and Corporate Finance Report Summary SPAR International - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Global Foundries Inc:企業のM&A・事業提携・投資動向
    Global Foundries Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Global Foundries Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Selective Insurance Group, Inc. (SIGI):企業の財務・戦略的SWOT分析
    Selective Insurance Group, Inc. (SIGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Belden Inc (BDC):企業の財務・戦略的SWOT分析
    Belden Inc (BDC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • CA, Inc.:企業のM&A・事業提携・投資動向
    CA, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's CA, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • Solocal Group (LOCAL):企業の財務・戦略的SWOT分析
    Solocal Group (LOCAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Laboratorios Farmaceuticos Rovi SA (ROVI):企業の財務・戦略的SWOT分析
    Summary Laboratorios Farmaceuticos Rovi SA (Rovi) is a pharmaceutical company engaged in the research, development, manufacturing, and marketing of prescription and hospital products. The company's product portfolio includes licensed prescription pharmaceuticals in the therapeutic areas of cardiovas …
  • NetSol Technologies, Inc. (NTWK):企業の財務・戦略的SWOT分析
    NetSol Technologies, Inc. (NTWK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Prescient Therapeutics Ltd (PTX):企業の財務・戦略的SWOT分析
    Summary Prescient Therapeutics Ltd (Prescient Therapeutics), formerly Virax Holdings Ltd, is a biotechnology company which develops novel medicines for cancer treatment. The company is investigating OmniCAR, an immune receptor platform that controls T-cell activity and multi-antigen targeting with a …
  • Bulgarian Energy Holding EAD:企業の戦略的SWOT分析
    Bulgarian Energy Holding EAD - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Dev Information Technology Ltd (DEVIT):企業の財務・戦略的SWOT分析
    Dev Information Technology Ltd (DEVIT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Forty Seven Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Forty Seven Inc (Forty Seven), formerly CD47 Sciences Inc is a clinical-stage immuno-oncology company that focuses on the development of therapies to treat cancer. The company’s lead molecule Hu5F9-G4 is a monoclonal antibody that is used against the CD47 receptor. Its monoclonal antibody is …
  • HIL Limited (HIL):企業の財務・戦略的SWOT分析
    HIL Limited (HIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Asbury Automotive Group, Inc.:企業の戦略・SWOT・財務情報
    Asbury Automotive Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Asbury Automotive Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Pharm-Olam International Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Pharm-Olam International Ltd (Pharm-Olam) is a contract research organization that offers clinical research services. The organization’s services include clinical trials, medical writing, medical monitoring, regulatory submissions, data management, biostatistics analysis, pharmacovigilance, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆